Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF +1.46%82 Graham Number is $18.13 as of Dec. 2025, which is 930% above its 10-year median of 1.76. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $27.94 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 604 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 64.4% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
The historical rank and industry rank for Hikma Pharmaceuticals's Graham Number or its related term are showing as below:
HKMPF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.14 Med: 1.76 Max: 2.73
Current: 1.21
During the past 13 years, the highest Price to Graham Number ratio of Hikma Pharmaceuticals was 2.73. The lowest was 1.14. And the median was 1.76.
HKMPF's Price-to-Graham-Number is ranked better than 64.4% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.515
vs HKMPF: 1.21
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Hikma Pharmaceuticals (OTCPK:HKMPF) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Hikma Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
21.56
/
18.13
=
1.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Hikma Pharmaceuticals Graham Number Related Terms
Hikma Pharmaceuticals Graham Number Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: Graham Number Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a Graham Number of $18.13 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on Hikma Pharmaceuticals and its competitors. This is 930% above median its historical median of 1.76. Over the past decade, Hikma Pharmaceuticals' Graham Number has ranged from 1.14 to 2.73. According to the industry distribution chart, Hikma Pharmaceuticals ranks #215 out of 604 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Hikma Pharmaceuticals' Graham Number too high?
Hikma Pharmaceuticals' current Graham Number of $18.13 is 930% above median its 10-year median of 1.76. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 2.73. The Drug Manufacturers industry median Graham Number is 1.52. Hikma Pharmaceuticals' value of $18.13 is 1096.7% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #215 out of 604 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Graham Number compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #215 out of 604 companies for Graham Number. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median Graham Number is 1.52. Hikma Pharmaceuticals' value of $18.13 is 1096.7% above this benchmark. Historically, Hikma Pharmaceuticals' own Graham Number has ranged from 1.14 to 2.73 over the past decade. While the company's 10-year median is 1.76 vs. the industry median of 1.52, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.52, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Graham Number of $18.13 is 1096.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Graham Number is $18.13, which is 930% above median its own 10-year median of 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.94, compared to a current price of $21.56 — trading 22.8% below its estimated fair value. The current Graham Number is $18.13, which is 930% above median its 10-year median of 1.76 and 1096.7% above the Drug Manufacturers industry median of 1.52. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Graham Number is $18.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.56 is trading 22.8% below its estimated GF Value™ of $27.94.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Graham Number: $18.13 (930% above median its 10-year median of 1.76)
GF Value™: $27.94 vs. price of $21.56 (22.8% below fair value)
Industry Position: 1096.7% above the Drug Manufacturers median (#215 of 604)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
